D.W. Hillman

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]”.

Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]

ESMO Open(2024)10.1016/j.esmoop.2024.103938

N/A

0DataRank · unranked

9 citations

M. Piccart-Gebhart, Shona Fielding, John Townend, D.W. Hillman, M. Colleoni +37 more

Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials

UNC Libraries(2024)10.17615/6kd2-qh45

N/A

0DataRank · unranked

0 citations

A Fernandez-Martinez, Françoise Rothé, EP Winer, David Venet, I.E. Krop +17 more